Education
About Us
Working with TipRanks
Follow Us
Prophase Labs (PRPH)
NASDAQ:PRPH
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.15Last Year’s EPS
-0.33Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 20, 2025
|% Change Since: -9.38%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
ProPhase Labs is navigating through financial challenges by implementing cost reductions and restructuring efforts. The company is focused on upcoming liquidity events, including the potential sale of Nebula Genomics and significant collections from Crown Medical, which are expected to improve its financial position. However, the shortfall in COVID testing revenue and challenges in maintaining NASDAQ compliance present ongoing risks.Company Guidance
In the call discussing ProPhase Labs' first quarter 2025 results, CEO Ted Karkus provided guidance highlighting several key metrics and expectations for the company. He emphasized the anticipated commercialization of the BE-Smart Esophageal Cancer Test later in the year, targeting approximately 7 million endoscopies annually in the U.S., with a potential reimbursement of $1,000 to $2,000 per test. Karkus also discussed the sale of Nebula Genomics, stating that the company's genomic data set is equivalent to over 150 million ancestry tests, and potential acquisition interest could align with the company's market cap. Additionally, he mentioned plans to address liquidity through debt financing, with expected substantial cash flow from Crown Medical collections and the sale of Nebula Genomics in the latter half of 2025. The company also addressed NASDAQ compliance, expecting a six-month extension to meet listing requirements, and outlined cost-cutting measures, including reducing headcount from 96 to 25 employees since December.Pharmaloz Manufacturing Sale
ProPhase Labs sold the Pharmaloz manufacturing facility for $23 million, which significantly increased their shareholders' equity and cleaned up the balance sheet.
Cost Reduction and Restructuring
ProPhase Labs has reduced its headcount from 96 employees to 25 and shut down the genomics laboratory, resulting in significant overhead cost reductions.
Potential Sale of Nebula Genomics
ProPhase Labs is exploring strategic alternatives for Nebula Genomics, including a potential sale, which could significantly increase the company's cash flow and assets.
BE-Smart Esophageal Cancer Test
The BE-Smart Esophageal Cancer Test has multibillion-dollar potential, targeting approximately 7 million endoscopies per year in the US. It aims to enhance endoscopy accuracy and is expected to be commercialized later in 2025.
Crown Medical Collections
Crown Medical is actively working on collecting outstanding COVID testing receivables, with potential significant cash inflows expected in the next few months.
Debt Financing and Liquidity Strategy
ProPhase Labs is focused on debt financing rather than issuing shares, anticipating significant liquidity events in the second half of 2025.
NASDAQ Listing Compliance
The company anticipates receiving a 6-month extension to maintain NASDAQ listing compliance, meeting all criteria except stock price.
PRPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PRPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 20, 2025 | $0.32 | $0.33 | +3.13% |
Mar 31, 2025 | $0.44 | $0.40 | -9.09% |
Nov 13, 2024 | $0.74 | $0.77 | +4.05% |
Aug 14, 2024 | $2.47 | $2.50 | +1.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Prophase Labs (PRPH) report earnings?
Prophase Labs (PRPH) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Prophase Labs (PRPH) earnings time?
Prophase Labs (PRPH) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PRPH EPS forecast?
PRPH EPS forecast for the fiscal quarter 2025 (Q2) is -0.15.